{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:57:56Z","timestamp":1753891076338,"version":"3.41.2"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002947","name":"Anhui Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>To investigate the efficacy and safety of combining Recombinant Human Endostatin Injection (marketed as Endo) with anti-PD-1 in elderly patients aged 80 and above with non-small cell lung cancer (NSCLC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Retrospective analysis of 181 patients with NSCLC aged 80 and above treated in the Department of Respiratory and Critical Care Medicine at Chaohu Hospital, affiliated with Anhui Medical University, from June 2019 to January 2024. Patients who received at least one cycle of combined Endo with anti-PD-1 were included based on inclusion criteria. Clinical and pathological data were collected, including complete blood count, liver and kidney function, electrocardiogram, coagulation function, thyroid function, cardiac enzymes, and whole-body imaging. Adverse events were recorded with a final follow-up on January 25, 2024. The primary endpoints were progression-free survival (PFS) and overall survival (OS), with safety as a secondary endpoint.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>This study involved 14 elderly patients with NSCLC aged over 80. Median progression-free survival (mPFS) was 102 days, and median overall survival (mOS) was 311 days. Subgroup analyses based on treatment cycles showed a non-significant 441-day mPFS increase in the long-term group (\u22656 cycles, 5 patients) compared to the short-term group (&amp;lt;6 cycles, 9 patients). However, the mOS in the long-term group significantly exceeded the short-term group by 141 days, with statistical significance (<jats:italic>P<\/jats:italic>=0.048). Further categorization revealed a 204-day shorter mPFS in the monotherapy maintenance group (Endo or Immunol) compared to the combination maintenance group (Endo combined with Immunol, 441 days). The mOS of the monotherapy maintenance group was longer (686 days) than the combination maintenance group (311 days), but no statistical significance (<jats:italic>P<\/jats:italic>= 0.710, 0.920). Throughout the treatment, 77 adverse events were recorded, mainly grade 1\u20132, with no new treatment-related reactions occurred. Overall, the safety of Endo combined with anti-PD-1 was considered good and manageable.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The combination of Endo and anti-PD-1 could be an effective treatment choice for patients with NSCLC aged 80 and above.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1402018","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T04:27:09Z","timestamp":1719203229000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A single-center, retrospective study-spring-evaluating the efficacy and safety of recombinant human vascular endothelial inhibitor combined with anti-PD-1 in elderly patients aged 80 and above with NSCLC"],"prefix":"10.3389","volume":"15","author":[{"given":"Tian","family":"Xing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianqian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongbin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianrong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganglin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1186\/s12885-021-08272-y","article-title":"Comorbidity in lung cancer patients and its association with hospital readmission and fatality in China","volume":"21","author":"Zhu","year":"2021","journal-title":"BMC Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01740-y","article-title":"Lung cancer immunotherapy: progress, pitfalls, and promises","volume":"22","author":"Lahiri","year":"2023","journal-title":"Mol Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2023.2211346","article-title":"Combined chemo-immunotherapy in advanced non-small cell lung cancer: feasible in the elderly","volume":"28","author":"Casaluce","year":"2023","journal-title":"Expert Opin Emerg Drugs"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2021.11.011","article-title":"International trends in cancer incidence in middle-aged and older adults in 44 countries","volume":"13","author":"Pilleron","year":"2022","journal-title":"J Geriatr Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20136736(18)32409\u20137","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13045\u2013020-00881\u20137","article-title":"Emerging therapeutic agents for advanced non-small cell lung cancer","volume":"13","author":"Chen","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.11.018","article-title":"Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-Sq): a phase 3 trial","volume":"17","author":"Ren","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.05.005","article-title":"Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous NSCLC (RATIONALE 304): a randomized phase 3 trial","volume":"16","author":"Lu","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3779\/j.issn.1009\u20133419.2021.102.02","article-title":"Research progress of small molecule anti-angiogenic drugs in non-small cell lung cancer","volume":"24","author":"Dou","year":"2021","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1038\/s41467-017-01599-w","article-title":"Loss of HIF-1\u03b1 in natural killer cells inhibits tumour growth by stimulating non-productive angiogenesis","volume":"8","author":"Krzywinska","year":"2017","journal-title":"Nat Commun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2174\/092986712799320673","article-title":"Bevacizumab in non small cell lung cancer: development, current status and issues","volume":"19","author":"Sandomenico","year":"2012","journal-title":"Curr Med Chem"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2020.02.024","article-title":"The story of angiogenesis inhibitors in non-small-cell lung cancer: the past, present, and future","volume":"21","author":"Shukla","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00432\u2013020-03129\u20136","article-title":"New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer","volume":"146","author":"Qiang","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109746","article-title":"Synergic effect of PD-1 blockade and endostar on the PI3K\/AKT\/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model","volume":"125","author":"Wu","year":"2020","journal-title":"BioMed Pharmacother"},{"key":"B16","doi-asserted-by":"publisher","first-page":"16468","DOI":"10.1038\/s41598-023-43122-w","article-title":"High endothelial venules predict response to PD-1 inhibitors combined with anti-angiogenesis therapy in NSCLC","volume":"13","author":"Ye","year":"2023","journal-title":"Sci Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5526","article-title":"Rh-endostatin plus camrelizumab and chemotherapy in first-line treatment of advanced non-small cell lung cancer: A multicenter retrospective study","volume":"12","author":"Pu","year":"2023","journal-title":"Cancer Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.critrevonc.2016.03.014","article-title":"Cisplatin versus carboplatin: comparative review of therapeutic management in solid Malignancies","volume":"102","author":"Ho","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.lungcan.2019.07.010","article-title":"Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis","volume":"135","author":"Griesinger","year":"2019","journal-title":"Lung Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ejca.2017.11.019","article-title":"Quality of life comparing carboplatin with cisplatin in the treatment of non-small cell lung cancer","volume":"91","author":"Snee","year":"2018","journal-title":"Eur J Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0366","article-title":"Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: A phase 3 randomized clinical trial","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1186\/s13045\u2013022-01242\u20132","article-title":"Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade via combination therapy and PD-L1 regulation","volume":"15","author":"Wu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00262\u2013019-02310\u20132","article-title":"Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors","volume":"68","author":"Nadal","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23755","article-title":"Newly developed anti-angiogenic therapy in non-small cell lung cancer","volume":"9","author":"Qu","year":"2017","journal-title":"Oncotarget"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s13277\u2013016-5031\u20130","article-title":"A retrospective analysis of efficacy and safety of adding bevacizumab to chemotherapy as first- and second-line therapy in advanced non-small-cell lung cancer (NSCLC)","volume":"37","author":"Quan","year":"2016","journal-title":"Tumour Biol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13445","article-title":"Complications following novel therapies for non-small cell lung cancer","volume":"291","author":"Skribek","year":"2022","journal-title":"J Intern Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1190001","article-title":"Association between immune-related adverse events and immunotherapy efficacy in non-small-cell lung cancer: a meta-analysis","volume":"14","author":"Lin","year":"2023","journal-title":"Front Pharmacol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1402018\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T04:27:15Z","timestamp":1719203235000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1402018\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,24]]},"references-count":28,"alternative-id":["10.3389\/fimmu.2024.1402018"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1402018","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2024,6,24]]},"article-number":"1402018"}}